Q1 EPS Estimates for TG Therapeutics Cut by HC Wainwright

Key Points

• HC Wainwright cut near‑term and multi‑year forecasts — the firm lowered Q1 2026 EPS to $0.17 from $0.24 (and trimmed Q2–Q4) and reduced FY2026 EPS to $0.94 from $1.21, signaling weaker expected momentum and upside for TG Therapeutics.
• Recent quarter missed EPS — TGT X reported $0.14 EPS (vs. $0.35 consensus) with revenue roughly in line at $192.57M, and shares traded down about 1.8% around $36.28 amid the revisions.
• Mixed analyst backdrop — the stock carries an average MarketBeat rating of "Moderate Buy" with a $50 consensus target, but several brokers have trimmed price targets or downgraded sentiment in recent months.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued on Monday, April 20th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.24. The consensus estimate for TG Therapeutics' current full-year earnings is $1.39 per share. HC Wainwright also issued estimates for TG Therapeutics' FY2026 earnings at $0.94 EPS.

TGTX has been the topic of several other reports. The Goldman Sachs Group increased their price target on TG Therapeutics from $37.00 to $39.00 and gave the stock a "neutral" rating in a report on Thursday, January 15th. Weiss Ratings reiterated a "hold (c+)" rating on shares of TG Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald reiterated an "overweight" rating on shares of TG Therapeutics in a report on Wednesday, January 14th. JPMorgan Chase & Co. reduced their price target on TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating on the stock in a report on Monday, February 2nd. Finally, Wall Street Zen downgraded TG Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $50.00.

TG Therapeutics Trading Down 1.8%

Shares of NASDAQ TGTX opened at $36.28 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The business's 50 day moving average price is $31.17 and its 200-day moving average price is $31.46. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The company has a market cap of $5.79 billion, a price-to-earnings ratio of 13.10 and a beta of 1.76.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The business had revenue of $192.57 million during the quarter, compared to analysts' expectations of $192.15 million. During the same quarter in the previous year, the company posted $0.15 earnings per share. The company's quarterly revenue was up 78.0% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TGTX. Danske Bank A S purchased a new position in TG Therapeutics during the 3rd quarter worth $25,000. Optiver Holding B.V. increased its holdings in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 732 shares during the period. Bessemer Group Inc. increased its holdings in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 486 shares during the period. Salomon & Ludwin LLC purchased a new position in TG Therapeutics during the 3rd quarter worth $34,000. Finally, Stone House Investment Management LLC purchased a new position in TG Therapeutics during the 3rd quarter worth $36,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Neutral Sentiment: Market consensus for the current full year remains at $1.39 EPS (HC Wainwright’s note references the same consensus). MarketBeat TGTX
• Negative Sentiment: HC Wainwright cut TG’s quarterly 2026 outlook: Q1 to $0.17 (from $0.24), Q2 to $0.20 (from $0.27), Q3 to $0.25 (from $0.31) and Q4 to $0.34 (from $0.41). These near‑term downgrades suggest weaker-than-expected momentum into upcoming reports and raise the risk of further analyst revisions. HC Wainwright note
• Negative Sentiment: HC Wainwright also lowered multi‑year targets: FY2026 EPS to $0.94 (from $1.21), FY2027 to $1.60 (from $1.86), FY2028 to $2.11 (from $2.37), FY2029 to $2.71 (from $2.97) and FY2030 to $3.66 (from $3.91). The downward revisions reduce near‑term and long‑term upside in analyst models. HC Wainwright multi-year cuts

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.